Home > Focus Areas > Migraine Connect > Post
  • Saved

3yr
Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies - PubMed

Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35687795/

doi: 10.1002/brb3.2662. Online ahead of print. 1 Department of Neurology and Centre for Translational Neuro- and Behavioural Sciences (C-TNBS), West German Headache Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 2 Department of Neurology and Centre for Translational Neuro- and Behavioural Sciences (C-TNBS), Division of Clinical Neurooncology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.


Conclusion: A mandatory break in CGRP (pathway) monoclonal antibody therapy had a negative short-term impact on migraine patients.

  • 3yr
    I wonder if this is necessary to do.
  • 3yr
    Key Points
    • Source: Brain and Behavior
    • Conclusions: “A mandatory break in CGRP (pathway) monoclonal antibody therapy had a negative short-term impact on migraine patients.”
    • The investigators assessed clinical data from 46 migraine patients: 14 with episodic migraine (EM) and 32 with chronic migraine (CM). These patients were treated with erenumab (n = 40), galcanezumab (n = 4), and fremanezumab (n = 2).
    • During the treatment break of 9 to 12 months, which is recommended by German and European guidelines, the average number of monthly migraine days (MMDs) in EM and CM patients went up. Patients also increased their intake of acute medications during the break. All patients ended up continuing CGRP after the treatment break.
    • The impact of long-term treatment with CGRP (pathway) mAbs on the over- or under-expression of CGRP receptors remains to be elucidated. Future studies should look at the best timing for treatment breaks with regard to such effects.
    • “Our real-world data suggest that the guideline suggestion of considering a treatment break after a year of treatment with CGRP-monoclonal antibodies results in a significant worsening of MMD [monthly migraine days], MHD [monthly headache days], AMD [acute medication], intensity of attacks, length of attacks as well as concomitant symptoms in most migraine patients when compared to levels at 12 months of CGRP (pathway) mAb treatment,” the authors wrote.
    • Some limitations of the current study include possible nocebo effect, a lack of understanding of how discontinuation affects those with a high number of migraine attacks but without CM or EM, and the single-center nature of the study.

You might also like